Treats schizophrenia. ANDA 218272, held by Aspiro. Chlorpromazine Hydrochloride.
As of Nov 16, 2026, ANDA 218272 (Chlorpromazine Hydrochloride), held by Aspiro, was first approved by FDA on Nov 18, 2024, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the followi…
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 18, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Chlorpromazine Hydrochloride25MG/ML · injectable;injection | Chlorpromazine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters